Table 1.
Demographic and clinical characteristics at baseline for the overall study population (n = 410) and stratified by number of ALK inhibitors received
| Overall (n = 410) | 1 ALK inhibitor (n = 233) | 2 ALK inhibitors (n = 144) | 3–4 ALK inhibitors (n = 33) | |
|---|---|---|---|---|
| Age at index, years | ||||
| Median (min, max) | 62 (20, 89) | 64 (27, 88) | 59 (20, 85) | 58 (30, 79) |
| Age distribution, n (%) | ||||
| 18–65 years | 238 (58.0) | 125 (53.6) | 91 (63.2) | 22 (66.7) |
| > 65 years | 172 (42.0) | 108 (46.4) | 53 (36.8) | 11 (33.3) |
| Sex, n (%) | ||||
| Female | 222 (54.1) | 126 (54.1) | 79 (54.9) | 17 (51.5) |
| Male | 188 (45.9) | 107 (45.9) | 65 (45.1) | 16 (48.5) |
| Ethnicity, n (%) | ||||
| Hispanic or Latino | 47 (11.5) | 24 (10.3) | 20 (13.9) | 3 (9.1) |
| Not Hispanic or Latino | 330 (80.5) | 187 (80.3) | 113 (78.5) | 30 (90.9) |
| Unknown | 33 (8.0) | 22 (9.4) | 11 (7.6) | 0 (0.00) |
| Race, n (%) | ||||
| Black or African American | 23 (5.6) | 14 (6.0) | 8 (5.6) | 1 (3.0) |
| Caucasian | 318 (77.6) | 182 (78.1) | 107 (74.3) | 29 (87.9) |
| Other | 26 (6.3) | 9 (3.9) | 14 (9.7) | 3 (9.1) |
| Missing | 43 (10.5) | 28 (12.0) | 15 (10.4) | 0 (0.00) |
| Smoking status at index, n (%) | ||||
| Current | 33 (8.0) | 24 (10.3) | 7 (4.9) | 2 (6.1) |
| Former | 151 (36.8) | 89 (38.2) | 51 (35.4) | 11 (33.3) |
| Never | 220 (53.7) | 117 (50.2) | 84 (58.3) | 19 (57.6) |
| Not recorded | 6 (1.5) | 3 (1.3) | 2 (1.4) | 1 (3.0) |
| ECOG status at index, n (%) | ||||
| 0 | 52 (12.7) | 25 (10.7) | 20 (13.9) | 7 (21.2) |
| 1 | 243 (59.3) | 135 (57.9) | 86 (59.7) | 22 (66.7) |
| 2 | 60 (14.6) | 41 (17.6) | 16 (11.1) | 3 (9.1) |
| 3 | 5 (1.2) | 4 (1.7) | 1 (0.7) | 0 (0.00) |
| 4 | 1 (0.2) | 0 (0.00) | 1 (0.7) | 0 (0.00) |
| Unknown | 49 (12.0) | 28 (12.0) | 20 (13.9) | 1 (3.0) |
| Disease stage at initial NSCLC diagnosis, n (%) | ||||
| IA | 11 (2.7) | 7 (3.0) | 3 (2.1) | 1 (3.0) |
| IB | 11 (2.7) | 5 (2.1) | 6 (4.2) | 0 (0.00) |
| IIA | 13 (3.2) | 11 (4.7) | 1 (0.7) | 1 (3.0) |
| IIB | 6 (1.5) | 5 (2.1) | 1 (0.7) | 0 (0.00) |
| IIIA | 37 (9.0) | 20 (8.6) | 15 (10.4) | 2 (6.1) |
| IIIB | 31 (7.6) | 18 (7.7) | 11 (7.6) | 2 (6.1) |
| IV | 291 (71.0) | 158 (67.8) | 106 (73.6) | 27 (81.8) |
| Unknown | 10 (2.4) | 9 (3.9) | 1 (0.7) | 0 (0.00) |
| Histology, n (%) | ||||
| Adenocarcinoma | 357 (87.1) | 192 (82.4) | 134 (93.1) | 31 (93.9) |
| Adenosquamous | 7 (1.7) | 4 (1.7) | 1 (0.7) | 2 (6.1) |
| Bronchioloalveolar | 3 (0.7) | 3 (1.3) | 0 (0.00) | 0 (0.00) |
| Squamous cell | 14 (3.4) | 11 (4.7) | 3 (2.1) | 0 (0.00) |
| Unknown | 14 (3.4) | 12 (5.2) | 2 (1.4) | 0 (0.00) |
| Unspecified NSCLC | 6 (1.5) | 4 (1.7) | 2 (1.4) | 0 (0.00) |
| Other | 9 (2.2) | 7 (3.0) | 2 (1.4) | 0 (0.00) |
| Chemotherapy prior to first ALKa, n (%) | ||||
| Yes | 243 (59.3) | 128 (54.9) | 83 (57.6) | 32 (96.9) |
| No | 167 (40.7) | 105 (45.1) | 61 (42.4) | 1 (3.0) |
ALK anaplastic lymphoma kinase, ECOG Eastern Cooperative Oncology Group, NSCLC non-small cell lung cancer
aPresence of any systemic antineoplastic chemotherapy prior to first ALK inhibitor